Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Regeneron Pharmaceuticals is a biotech company headquartered in New York. While it works on a number of drugs and diseases, it's most recently been in the news for REGN-COV2 — the experimental antibody cocktail.
The antibody cocktail is being studied as a possible treatment for the novel coronavirus.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
REGN-COV2 is Regeneron’s experimental COVID-19 treatment. It’s a combination of two antibodies designed to help the immune system recover from illness.
While interest waned as vaccines began to circulate, the stock has risen with more interest in the treatment as COVID resurges.
Since the stock market crash in March caused by coronavirus, Regeneron Pharmaceuticals's share price has had significant positive movement.
Its last close price was $590.50, which is 31.73% up on its pre-crash value of $403.15 and 73.99% up on the lowest point reached during the March crash when the shares fell as low as $339.39.
If you had bought $1,000 worth of Regeneron Pharmaceuticals shares at the start of February 2020, those shares would have been worth $1.00 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1.00.
| Open | $593.92 |
|---|---|
| High | $594.53 |
| Low | $583.66 |
| Close | $590.50 |
| Previous close | $595.40 |
| Change | $-4.90 |
| Change % | -0.823% |
| Volume | 308,444 |
| 52-week range | $538.01 - $747.42 |
|---|---|
| 50-day moving average | $631.61 |
| 200-day moving average | $632.16 |
| Wall St. target price | $689.18 |
| PE ratio | 8.3859 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $71.00 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $590.5 from 2022-07-01
| 1 week (2022-06-28) | -0.66% |
|---|---|
| 1 month (2022-06-01) | -10.38% |
| 3 months (2022-04-04) | -15.45% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | 1.18% |
|---|---|
| 2 years (2020-07-02) | -5.13% |
| 3 years (2019-07-05) | 92.35% |
| 5 years (2017-07-05) | 18.81% |
Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Regeneron Pharmaceuticals shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.2426. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $9.4 billion.
The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $16.5 billion |
|---|---|
| Operating margin TTM | 55.25% |
| Gross profit TTM | $10.7 billion |
| Return on assets TTM | 25.84% |
| Return on equity TTM | 49.75% |
| Profit margin | 48.06% |
| Book value | $185.41 |
| Market capitalisation | $65.4 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 22.33
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.51/100
Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 13.94/100
Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.88/100
Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.
Regeneron Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 22.33 |
|---|---|
| Total ESG percentile | 26.82 |
| Environmental score | 1.51 |
| Environmental score percentile | 2 |
| Social score | 13.94 |
| Social score percentile | 2 |
| Governance score | 5.88 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $538.01 up to $747.42. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2446. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd. ; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
